Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RSV/hMPV mRNA Vaccine in Healthy Adults
NCT06237296Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jan 2024
- Primary completion
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of SP0256 in respiratory syncytial virus infection (RSV) and human metapneumovirus infection (HMPV) (7 arms), sponsored by Sanofi. Primary endpoints: Presence of unsolicited systemic immediate adverse events, Presence of solicited injection site or systemic reactions and 6 more. Started Jan 2024; status: completed.
02
Drugs
SP0256
03
Conditions
respiratory syncytial virus infection (RSV)human metapneumovirus infection (HMPV)
Beyond the preview
Go deeper on NCT06237296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06237296.